CL2024001833A1 - Composiciones y métodos para la prevención de la miocarditis piscina - Google Patents
Composiciones y métodos para la prevención de la miocarditis piscinaInfo
- Publication number
- CL2024001833A1 CL2024001833A1 CL2024001833A CL2024001833A CL2024001833A1 CL 2024001833 A1 CL2024001833 A1 CL 2024001833A1 CL 2024001833 A CL2024001833 A CL 2024001833A CL 2024001833 A CL2024001833 A CL 2024001833A CL 2024001833 A1 CL2024001833 A1 CL 2024001833A1
- Authority
- CL
- Chile
- Prior art keywords
- pool
- myocarditis
- prevention
- compositions
- methods
- Prior art date
Links
- 208000009525 Myocarditis Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 241000251468 Actinopterygii Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291577P | 2021-12-20 | 2021-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001833A1 true CL2024001833A1 (es) | 2024-10-18 |
Family
ID=85173073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001833A CL2024001833A1 (es) | 2021-12-20 | 2024-06-18 | Composiciones y métodos para la prevención de la miocarditis piscina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250127873A1 (https=) |
| EP (1) | EP4453008A1 (https=) |
| JP (1) | JP2025503468A (https=) |
| CN (1) | CN118434755A (https=) |
| CA (1) | CA3242834A1 (https=) |
| CL (1) | CL2024001833A1 (https=) |
| DK (1) | DK202470172A1 (https=) |
| WO (1) | WO2023122525A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4208157A1 (en) | 2020-09-04 | 2023-07-12 | Elanco Us Inc. | Palatable formulations |
| DK202370610A1 (en) * | 2022-12-13 | 2024-07-12 | Zoetis Services Llc | Methods of vaccine administration to salmonids |
| CN120393054B (zh) * | 2025-04-21 | 2026-01-27 | 华南农业大学 | 一种核酸递送载体、递送系统及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2650730A1 (en) | 2006-04-27 | 2007-11-08 | Pikamab, Inc. | Methods and compositions for antibody therapy |
| CA2796178C (en) | 2010-04-21 | 2021-02-16 | Pharmaq As | Nucleic acid sequences of fish cardiomyopathy syndrome virus and the use thereof |
| GB201013153D0 (en) | 2010-08-04 | 2010-09-22 | Touchlight Genetics Ltd | Primer for production of closed linear DNA |
| GB201415789D0 (en) | 2014-09-05 | 2014-10-22 | Touchlight Genetics Ltd | Synthesis of DNA |
| US10456459B2 (en) | 2015-07-20 | 2019-10-29 | Zoetis Services Llc | Liposomal adjuvant compositions |
| CN109844134B (zh) | 2016-08-16 | 2023-05-05 | 塔驰莱特Ip有限公司 | 闭合线性dna的生产 |
| GB2559193A (en) * | 2017-01-31 | 2018-08-01 | Pharmaq As | Virus-like particle |
| WO2018224516A1 (en) * | 2017-06-06 | 2018-12-13 | Fish Vet Group Norge As | Detection and treatment of pmcv infection in cleaner fish |
| GB201805683D0 (en) | 2018-04-05 | 2018-05-23 | Touchlight Ip Ltd | Reprogramming vectors |
| GB202002068D0 (en) | 2020-02-14 | 2020-04-01 | Touchlight Ip Ltd | DNA synthesis yield improvements |
-
2022
- 2022-12-19 US US18/721,719 patent/US20250127873A1/en active Pending
- 2022-12-19 JP JP2024537383A patent/JP2025503468A/ja active Pending
- 2022-12-19 CA CA3242834A patent/CA3242834A1/en active Pending
- 2022-12-19 EP EP22854345.0A patent/EP4453008A1/en active Pending
- 2022-12-19 WO PCT/US2022/081914 patent/WO2023122525A1/en not_active Ceased
- 2022-12-19 CN CN202280084448.9A patent/CN118434755A/zh active Pending
-
2024
- 2024-06-18 CL CL2024001833A patent/CL2024001833A1/es unknown
- 2024-06-19 DK DKPA202470172A patent/DK202470172A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023122525A1 (en) | 2023-06-29 |
| US20250127873A1 (en) | 2025-04-24 |
| DK202470172A1 (en) | 2024-07-12 |
| JP2025503468A (ja) | 2025-02-04 |
| CN118434755A (zh) | 2024-08-02 |
| EP4453008A1 (en) | 2024-10-30 |
| CA3242834A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001833A1 (es) | Composiciones y métodos para la prevención de la miocarditis piscina | |
| CL2024001582A1 (es) | Compuestos terapéuticos para la infección por el virus vih | |
| MX2022011671A (es) | Vacunas contra el coronavirus y metodos de uso. | |
| CL2019000415A1 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih. | |
| MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
| CR20150454A (es) | Compuestos amida para el tratamiento de vih | |
| EA202190854A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| MX2023013140A (es) | Vacunas contra el virus de la hepatitis b. | |
| BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
| CL2021003388A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| ECSP21079317A (es) | Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) | |
| CL2021001753A1 (es) | Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253). | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| ECSP20056232A (es) | Régimen posológico del modulador del ensamblaje de la cápside | |
| MX2022009176A (es) | Metodo y composiciones para el tratamiento de infeccion por coronavirus. | |
| MX2021004859A (es) | Vacuna de ibv h52 con proteina espicular heterologa. | |
| CL2024003287A1 (es) | Virus para vacuna contra el síndrome respiratorio y reproductivo porcino. | |
| CO2020000021A2 (es) | Método para preparar reserva de cepas víricas de trabajo para la influenza, método para preparar la vacuna contra la influenza usando la misma reserva de cepas, y la reserva de cepas víricas preparadas por el mismo método | |
| MX2019001412A (es) | Compuestos de 9-aminometil minociclina y usos de los mismos. | |
| AR056733A1 (es) | Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos | |
| CL2009000287A1 (es) | Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav. | |
| MX2022003442A (es) | Composiciones de trazodona pediatrica y metodo de tratamiento con las mismas. | |
| MX2018009543A (es) | Metodo para tratar la infección por el virus del zika con composiciones que contienen quercetina. | |
| CO2022016537A2 (es) | Vacuna inactivada para sars-cov-2 y preparación de la misma | |
| MX2022008062A (es) | Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d. |